PARTICIPATION IN CALGB

UMCC与CALGB有着长期的合作关系。 UMCC员工 参与行政、科学、委员会和规划 在CALGB的活动。 UMCC教师设计，指挥和椅子 研究并将患者输入多个CALGB协议。 资金来 继续并扩大这些活动将使UMCC得以发展 内部I期（2-4/年）研究分为II期研究组。 UMCC也 进行试点研究，这些研究为集团范围内的 问题研究 UMCC看到许多新的急性白血病患者，资金将 加强UMCC参与和这些患者进入CALGB研究。 UMCC的专业实验室，包括细胞遗传学和药理学 将作为协作努力和创新数据库的资源 为今后的研究做准备。 UMCC及其合作机构（VA 医院，巴尔的摩）和医生（Lichtenfeld博士，Lichtenfeld和 Sachs）建议每年将80至90名患者纳入CALGB研究。 参与CALGB研究将使UMCC以及合作 医生为患有这些疾病的患者提供更多的治疗选择。 UMCC已经完成了内部ANLL研究，旨在验证来自 另一组成员。 目前的参与包括患者的进入 进行大剂量抗白血病的初步研究。 辅助 活动是评估细胞药理学和敏感性， Ara-C以及白血病细胞的细胞遗传学，使用两种标准 和甲氨蝶呤同步的高分辨显带技术。 试点 急性白血病研究包括临床和药代动力学II期 研究药物，如AZQ高剂量Ara-C， 与另外的药剂和体外分化剂组合。 A UMCC 5-氮杂胞苷和依托泊苷研究导致了CML的CALGB方案， 爆炸危机 所有在UMCC看到的乳腺癌患者都被输入到 CALGB研究和近10%的IV期研究招募来自UMCC。 目前的第四阶段研究和几个第二阶段研究已经设计， 并在UMCC担任主席。 小细胞肺癌的UMCC研究 建立了一个积极的三种药物组合， 目前正在进行一项试点研究， 可能会作为新的广泛疾病方案的一部分 疾病 UMCC还将参加选定的CALGB II期研究， 小细胞肺癌和非小细胞肺癌。 不常见的患者 软组织肉瘤等肿瘤将被输入组间 通过CALGB进行研究。 这笔赠款将允许UMCC进入患者 CALGB研究，参加CALGB委员会，培养优秀飞行员 协议，监控和收集数据，为UMCC带来互利 的CALGB。

The UMCC has a longstanding relationship with CALGB. UMCC staff participate in administrative, scientific, committee and planning activities within the CALGB. The UMCC faculty design, conduct and chair studies and enter patients onto multiple CALGB protocols. Funding to continue and expand these activities will allow for the evolution of UMCC in-house phase I(2-4/year) studies into group phase II studies. UMCC also conducts pilot studies which have formed the conceptual basis for groupwide studies. UMCC sees many new patients with acute leukemia and funding will enhance UMCC participation and entry of these patients onto CALGB studies. Specialized laboratories at UMCC including cytogenetics and pharmacology will serve as a resource for collaborative efforts and innovative data base for future CALGB studies. UMCC and its collaborating institutions (VA Hospital, Baltimore) and physicians, (Drs. Lichtenfeld, Lichtenfeld and Sachs) propose to enter 80 to 90 patients per year onto CALGB studies. Participation in CALGB studies will allow UMCC as well as collaborating physicians greater treatment options for patients with these diseases. UMCC has completed its in-house ANLL study seeking to verify data from another group member. Current participation includes the entry of patients with leukemia on to a pilot study of high dose maintainence. Ancillary activities are evaluating the cellular pharmacology and sensitivity of Ara-C as well as the cytogenetics of leukemia cells utilizing both standard and methotrexate sychronized high resolution banding techniques. Pilot studies in acute leukemia include clinical and pharmacokinetic phase II studies of investigational agents such as AZQ high dose Ara-C in combination with additional agents and in vitro differentiators. A UMCC study of 5-Azacytidine and etoposide led to a CALGB protocol for CML in blast crisis. All breast cancer patients seen at UMCC are entered onto CALGB studies and nearly 10% of stage IV study accrual has come from UMCC. The current stage IV study, and several phase II studies have been designed and chaired at UMCC. UMCC studies in small cell lung cancer have established an active three drug combination which will serve as the basis for a pilot study currently being proposed for group activation and is likely to serve as a portion of the new extensive disease protocol for this disease. UMCC will also participate in selected CALGB phase II studies in both small cell and non-small cell lung cancer. Patients with uncommon tumors such as soft tissue sarcomas will be entered onto the intergroup studies through CALGB. This grant will allow UMCC to enter patients onto CALGB studies, participate on CALGB committees, develop meritorious pilot protocols, monitor and collect data to produce mutual benefit to the UMCC and CALGB.